CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Exelixis, Inc. v. Handa Pharmaceuticals, Inc.

1:26-cv-00813

Overview

Case Number 1:26-cv-00813
Filing Date 2026-07-06
Status Terminated
Termination Date 2026-08-31
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Handa Pharmaceuticals, Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Plaintiff

Exelixis, Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 19 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (19): πŸ‡ΊπŸ‡Έ US 🌐 PCT
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

5 Patents

There are 5 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US9174947
c-Met modulators and methods of use
Filed: 2006-10-26
Issued: 2015-11-03
Active (3.3 yrs remaining) +1225d PTA
Expires: 2030-03-04
US9365516
Process for preparing quinoline derivatives
Filed: 2012-10-22
Issued: 2016-06-14
Active (5.9 yrs remaining)
Expires: 2032-10-22
US9969692
Process for preparing quinoline derivatives
Filed: 2016-04-20
Issued: 2018-05-15
Active (9.4 yrs remaining)
Expires: 2036-04-20
US10123999
Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
Filed: 2016-11-10
Issued: 2018-11-13
Active (10.0 yrs remaining)
Expires: 2036-11-10
US10736886
Methods of using c-Met modulators
Filed: 2019-01-18
Issued: 2020-08-11
Active (12.2 yrs remaining)
Expires: 2039-01-18

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Active Threat

Active Threat β€” Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+1225 days) / Cellect Scrutiny β€” Over 1225 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

4

Dispositive

0

Granted

0

Denied

0

Pending / Review

2

Motions by Category

Procedural / Extension Motion 4

Key Dispositive Motions & Rulings

Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME for Defendants to answer, move or otherwise respond to Plaintiff's Complaint (D.I. 1) to September 8, 2026 - filed by Handa Oncology,...
Entry #21 • 2026-08-13 Document →
Procedural / Extension Motion Pending
SO ORDERED, re 21 Stipulation and Order to Extend Time for Defendants to answer, move or otherwise respond to Plaintiff's Complaint to September 8, 2026. (*Rese...
Entry #β€” • 2026-08-13
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME for Defendants to answer, move or otherwise respond to Plaintiff's Complaint to August 18, 2026 - filed by Handa Oncology, LLC, Handa...
Entry #12 • 2026-07-27 Document →
Procedural / Extension Motion Pending
SO ORDERED, re 12 Stipulation and Order to Extend Time for Defendants to answer, move or otherwise respond to Plaintiff's Complaint to August 18, 2026. (*Reset ...
Entry #β€” • 2026-07-27

Docket Entries

(46 total)
Pleading / Complaint

COMPLAINT for Patent Infringement against Handa Oncology, LLC, Handa Pharma, Inc., Handa Pharmaceuticals, Inc. (Filing fee $ 405, receipt number ADEDC-5009032) - filed by Exelixis, Inc. (Attachments: # 1 Exhibits A-G, # 2 Civil Cover Sheet)(mrr) (Entered: 07/07/2026)

Entry #1 • 2026-07-06
1
Pleading / Complaint

COMPLAINT for Patent Infringement against Handa Oncology, LLC, Handa Pharma, Inc., Handa Pharmaceuticals, Inc. (Filing fee $ 405, receipt number ADEDC-5009032) - filed by Exelixis, Inc. (Attachments: # 1 Exhibits A-G, # 2 Civil Cover Sheet)(mrr) (Entered: 07/07/2026)

Entry #1 • 2026-07-06
2
Pleading / Complaint

COMPLAINT for Patent Infringement against Handa Oncology, LLC, Handa Pharma, Inc., Handa Pharmaceuticals, Inc. (Filing fee $ 405, receipt number ADEDC-5009032) - filed by Exelixis, Inc. (Attachments: # 1 Exhibits A-G, # 2 Civil Cover Sheet)(mrr) (Entered: 07/07/2026)

Entry #1 • 2026-07-06
2

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mrr) (Entered: 07/07/2026)

Entry #2 • 2026-07-06
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,174,947 B2; 9,365,516 B2; 9,969,692 B2; 10,123,999 B2 ; 10,736,886 B2. (mrr) (Entered: 07/07/2026)

Entry #3 • 2026-07-06
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc